Summary HMFGI tumour associated monoclonal antibody IgGl and F(ab')2 fragments were radiolabelled with indium-111 and used to study patients with breast cancer. In vitro and in vivo stability of the radiolabelled antibodies was shown to be satisfactory. Thirty patients with primary breast cancer underwent tumour resection and quantitative evaluation of the radioactivity in the tumour and normal tissues following administration of specific and non-specific antibodies. The mean tumour uptake of HMFG1 F(ab')2 fragments at 24h was significantly higher (P<0.05) than the intact IgG but at 48h there was no difference. The mean tumour uptake with the specific antibody was higher than the non-specific antibody of the same subclass (P<0.05). Lymph node metastases showed higher antibody uptake than the corresponding primary tumours (P<0.05). Fifteen patients with primary or metastatic breast cancer were investigated by external body scintigraphy using HMFG1 F(ab')2 fragments. Successful localisation was observed in approximately 50% of the primary and metastatic lesions with no false positive results. All the patients had observable concentration of "'1In in the liver (20% of the injected dose), the kidneys and the spleen. Following i.v. administration, F(ab')2 fragments cleared from the blood more rapidly than the intact IgG. We conclude that HMFG1 F(ab')2 fragments can localise specifically and faster than intact IgG in breast cancer but the sensitivity of the radioimmunoscintigraphy is relatively low. This method needs further improvement before becoming clinically useful for detecting and staging breast cancer.
Radiolabelled monoclonal antibodies raised against human tumour associated antigens have been shown to localise preferentially to tumours, both clinically and in experimental animals (Mach et al., 1981; Epenetos et al., 1982; Farrands et al., 1982; Granowska et al., 1986) . Several investigators have reported successful radioimmunolocalisation of breast cancer (Colcher et al., 1983; Rainsbury, 1984; Kalofonos et al., 1988b) , but limitations of this approach are the low absolute amount of antibody reaching the target (Epenetos et al., 1986) , the heterogeneity of antigenic expression in tumour cells affecting antibody binding (Buchegger et al., 1983) and the persistence of high levels of blood pool radioactivity which makes tumour radioimmunodetection difficult. Several methods have been reported to reduce the blood pool activity. Begent et al. (1982) reported that liposomally entrapped second antibody could be used to improve tumour to blood ratios 10-fold in comparison to the primary antibody alone. A second alternative is the use of antibody fragments, enhancing the rate of radioactive antibody removal from the blood so tumour could be visualised earlier (Wahl et al., 1983; Khaw et al., 1984) .
In this study we report our experience using 1"1In-labelled F(ab')2 fragments as well as intact HMFG1 monoclonal antibody in patients with breast cancer. The aim of this study was to investigate kinetics, localising efficiency and specificity of HMFG1 F(ab')2 fragments compared to intact monoclonal antibody.
Patients, materials and methods

Patients
Two groups of patients were studied. The first consisted of 15 patients with primary and/or metastatic breast cancer, who were studied by external body scintigraphy. The patients' ages ranged from 38 to 72 years (mean 53). All the patients received 1 mCi of "11In-labelled HMFG1 F(ab')2 fragments as an i.v. bolus over 1 min.
The second group consisted of 30 patients with primary al., 1981) , is a murine IgGI directed against a mucin molecule which is strongly expressed in lactating breast as well as in a range of neoplasms of epithelial origin such as breast, ovarian, gastrointestinal and non-small cell lung cancer . It also reacts weakly with normal non-lactating breast and other normal epithelial tissues. It is, therefore, not tumour-specific but it can be described as a tumour-associated antibody. Purity of the antibody was confirmed by isoelectric focusing (Awdeh et al., 1968) and by polyacrylamide gel electrophoresis (Laemmli, 1976) . F(ab')2 fragments were produced by pepsin digestion (Nisonoff et al., 1960) as described elsewhere (Kalofonos et al., 1988a) . 4C4 The monoclonal antibody 4C4 (Boniolo et al., 1982 ) is a mouse IgGI directed against the hepatitis B surface antigen. This antibody does not react with neoplasms of epithelial origin such as breast cancer, or with any other human tissues and was used as a negative control. F(ab')2 fragments of the 4C4 monoclonal antibody were kindly provided by Sorin Biomedica (Saluggia, Italy).
Radiolabelling
Monoclonal antibodies were conjugated with DTPA (diethylene triamino pentaacetic acid) using the cyclicanhydride form (Sigma) followed by radiolabelling with 11'In (molarity 0.04M, carrier-free, Amersham Int., UK) as described by Hnatowich et al. (1983) . The labelled antibody Br. J. Cancer (1989), 59, 939-942 C The Macmillan Press Ltd., 1989 was separated from free IIIIn using gel filtration (Sephadex G 50 Kinetic studies Blood samples were taken at various intervals and urine was collected for 5 days following the administration of the antibody. Aliquots of the plasma and urine were counted in a gamma-counter along with a standard of the injectate for clearance studies.
Blood in heparinised tubes was centrifuged and the pellet was washed twice in order to quantitate the radioactivity in the pellet and the supernatant. Protein bound indium in the plasma was quantitated by chromatography (Sephadex G50) . In vitro and in vivo stability of the indium-labelled antibodies was assessed by SDS-polyacrylamide gel electrophoresis and autoradiography as described elsewhere (Kalofonos et al., 1988a) .
Imaging studies Antibody scans were generated in 15 patients with primary or metastatic breast cancer, using a 40 cm field-of-view gamma-camera with a medium energy collimator. Imaging studies were carried out on at least three points in every patient. Anterior and posterior whole body scans as well as spot views were obtained. The relative percentage of activity in the liver was calculated from the whole body scans by dividing the geometric mean of the counts in the liver by the geometric mean of the counts in the whole body.
Results
Radiolabelling
Monoclonal antibodies were conjugated with DTPA and radiolabelled with "1'In resulting in approximately one molecule of indium being attached onto one molecule of antibody as described by Hnatowich et al. (1983) . Labelling efficiencies of 85-90% were achieved. Specific activity was in the range of 3-5 mCi mg-1. No significant loss of the immunoreactivity of the F(ab')2 fragments was found in comparison with the intact IgG, and no significant loss was found before and after DTPA coupling and radiolabelling. and 4C4 F(ab')2 fragments were negative against all breast tissues.
Biodistribution study Table I summarises the biodistribution of indium labelled antibodies in breast cancer patients. The mean tumour uptake with HMFG1 F(ab')2 fragments at 24 h was 5.8 x 10-3% of injected dose per gram of tissue (Figure 1 ). This was significantly higher than whole IgG, 2.9 x 10-3% IDg-1 (P<0.01) and non-specific antibody 1.7x 10-3%IDg-1 (P<0.05). At 48h there was no significant difference between F(ab')2 fragments (5.9 x 10-3% IDg-1) and intact IgG (6.9 x 10-3% IDg-1), but both were higher than the non-specific antibody uptake 1.6 x 10-3% IDg-1 (P<0.05). Lymph node metastases, interestingly, showed higher antibody uptake than the correspondingly primary tumours (Table I ) (P< 0.05). However, although lymph nodes with tumour infiltration showed higher antibody uptake than normal lymph nodes the difference was not statistically significant.
Kinetic studies Blood clearance was identical for both HMFG1 and 4C4 F(ab')2 fragments. This was biphasic with a mean half-life of the first component T1 12a = 2.5 + 1.3 h and of the second component Tl/2b =48+4.5h. The HMFG1 intact antibody was cleared from the blood more slowly with T1/2a =24+2.8 and T112b = 58 + 3.8 h (Figure 2) . The cumulative urinary excretion of the indium label over 5 days was 10.6+2.6 and 9.8 + 2.8% of the injected dose in the patients studied with Time (hours) Figure 2 Half-life of the radiolabelled HMFGI intact IgG and F(ab')2 fragments in the blood.
F(ab')2 fragments and the intact antibody respectively. In all the patients studied, the majority of the radioactivity (95%) was associated with the plasma rather than the blood cells. (Figure 3 ), in four out of six patients with bone metastases, in two out of four with skin metastases, in one out of two with lymph node infiltration and in one out of two with liver metastases. The gamma-camera images showed considerable uptake of radioactivity by liver. There was also significant uptake by spleen and kidneys. The relative fraction of the injected radioactivity in the liver over 4 days remained constant, which was estimated to be approximately 20% of the administered dose.
Discussion
This study shows that the amount of "11In-labelled F(ab')2 fragments and intact HMFG1 monoclonal antibody reaching target tissues after i.v. administration is relatively small. However, it clearly demonstrates the ability of this antibody to bind specifically to breast cancer lesions resulting in successful immunolocalisation of approximately 50% of cancer lesions.
One objective of this study was to assess the localising This could be explained by the faster clearance of blood pool radioactivity along with faster tumour accretion after administration of the F(ab')2 fragments. These findings favour the use of F(ab')2 fragments for tumour radioimmunolocalisation and are in agreement with our previous experience (Kalofonos et al., 1988a) and the experience of others (Wahl et al., 1983; Buraggi et al., 1985; Munz et al., 1986; Chatal et al., 1987) . Bone metastases were detected in a higher percentage (67%) than the primary tumour (43%) or metastases in other organs (50%) possibly due to the easier access of the antibody to bone metastases through the rich medullary blood supply. In this study we observed significant non-specific concentration of the 11'In in the liver, the spleen and the kidneys. The accumulation of 111In in the kidneys with the F(ab')2 fragments may be due to antibody catabolism (Covell et al., 1986) , active filtration (Khaw et al., 1984) and exchange of 111In into ion-binding proteins within this organ. Accumulation of 111In by the liver is not well understood and could be a result of antibody catabolism and exchange with iron-binding protein (Sands & Jones, 1987) . Most of the previous clinical trials using radiolabelled monoclonal antibodies have relied solely on scans to determine the accuracy of tumour binding by the monoclonal antibody. In only a few trials have actual tumour biopsy material been obtained for direct analysis of monoclonal antibody delivery (Epenetos et al., 1986; Esteban et al., 1987; Ward et al., 1987) . In this study it became obvious that antibody localisation to the target was relatively small. However, we observed significantly higher specific antibody uptake than the irrelevant antibody by primary breast tumours. There are different factors which could account for the low accessibility of monoclonal antibodies in the tumours including the lack of vascularity as well as the amount and the type of interstitial stroma (Sands et al., 1988; Jain, 1987) . Breast cancer has a dense stromal component which may inhibit the accessibility of the antibody to reach all the antigen expressing tumour cells in different areas of the tumour. Another important observation in this study was that the F(ab')2 fragments accumulated in the tumour faster, with maximum uptake being achieved as early as 24 h, compared to the intact antibody where it was gradually increased and equivalent uptake achieved at 48h. F(ab')2 fragments with molecular weight lower than intact IgG and comparable immunoreactivity are cleared faster from the vascular moving to the extravascular compartment, resulting in an increase in tumour to background ratio.
In conclusion, this study demonstrates that "'In-labelled HMFG1 F(ab')2 fragments can specifically localise breast cancer lesions, but results obtained so far are inferior to conventional radiology such as isotope bone scanning. F(ab')2 fragments localise faster in the tumour than the intact antibody and are cleared faster from the blood pool, favouring their use for in vivo tumour localisation. However, this study also illustrates the relatively low antibody uptake of both IgG and F(ab')2 fragments by breast cancer. This method needs further improvement before becoming useful in clinical practice.
